CClinicalTrials.gg
RecruitingNCT06109324SCORESUpdated Oct 15, 2024

Sensory and Cognitive Outcomes of Robotic Exercises in Stroke (SCORES)

An interventional study of Robotic Rehabilitation of the upper limb and Conventional Rehabilitation of the upper limb in Stroke, sponsored by Fondazione Don Carlo Gnocchi Onlus. Recruiting at 3 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Based on the findings of meta-analyses, upper limb robotic rehabilitation has shown to enhance daily living activities, motor function, and strength in stroke patients. However, when compared to traditional methods, recent randomized controlled trials conducted on larger participant groups failed to identify significant differences in motor-related outcomes between the two approaches.

In addition to motor deficits, stroke survivors often experience cognitive decline and sensory disturbances, which can significantly impede their recovery process. The introduction of multisensory stimulation and an enriched environment through robotic interventions may offer valuable supplementary treatments in these specific areas. Nevertheless, this aspect of treatment has not been thoroughly explored.

This study seeks to assess the effectiveness of upper limb robotic rehabilitation in individuals recovering from subacute strokes, in comparison to conventional treatments. Specifically, it aims to determine whether this robotic therapy can lead to improvements in (a) cognitive deficits, (b) somatosensory impairment, and (c) how these sensory and cognitive deficits influence the process of motor recovery.

Read the detailed description

The study aims to investigate whether an upper limb robotic treatment could have a greater impact than a conventional approach on specific cognitive domains in patients with stroke, as well as in restoring the somatosensory impairment in patients with stroke.

For this aim, 126 consecutive subjects with stroke in the sub-acute phase (within 6 months after stroke) will be enrolled and randomized to either the robotic (RG) or the conventional group (CG). The sample size was calculated by means of a 2- sided, 2-sample t-test assuming: 80% power; type I error of 0.05; a mean difference of 2.15 units on the MoCA, a common standard deviation of 3.77 points (Wu 2019). Considering a dropout rate of 20%, the final sample size required was estimated to be 126 subjects.

Randomization will be stratified according to a cut-off of 18.28 on the MoCA demographically adjusted total score (inner confidence limit of the 5th centile of the normal population) indicating a borderline performance, to ensure that the subjects' characteristics in each group will be closely matched. In the RG, patients will undergo robotic therapy, while a conventional approach will be used in the CG. The rehabilitation treatments, either robotic or conventional, will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions. Patients in the RG will be treated using a set of devices that allow bi- and three-dimensional movements of the shoulder, elbow, wrist, and fingers (Aprile et al, 2019). Motor and cognitive tasks, carefully selected among those available, will be performed during the treatment, following a protocol already proposed in a previous pilot study (Aprile et al, 2021). Visual and auditory feedback will be provided to help the patients. In the RG, treatment will focus on reprogramming sensorimotor function, hypertonus inhibition, and functional improvement. Patients will be evaluated at baseline (T0), the end of the rehabilitation protocol (T1), and a 6-month follow-up (T2).

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • robotics
  • cognition
  • rehabilitation
  • upper extremity
  • sensorimotor
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 126 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Fondazione Don Carlo Gnocchi Onlus is the lead sponsor of 146 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • a single event, verified by MRI or CT;
  • age between 18 and 85 years;
  • time since stroke within six months;
  • a demographically adjusted total score of the Montreal Cognitive Assessment (MoCA) between 15.5 and 22.23

Exclusion criteria

Exclusion Criteria:

  • behavioural and cognitive disorders and/or reduced compliance that would interfere with active therapy;
  • fixed contraction deformity in the affected limb that would interfere with active therapy (ankylosis, Modified Ashworth Scale = 4);
  • severe deficits in visual acuity.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Robotic Rehabilitation

    Other: Robotic Rehabilitation of the upper limb

  • Active comparator
    Conventional treatment

    Other: Conventional Rehabilitation of the upper limb

Interventions

  • OtherRobotic Rehabilitation of the upper limb

    Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion). The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.

  • OtherConventional Rehabilitation of the upper limb

    Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement. The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.

06

What researchers measure

Primary outcomes

  1. Changes in Montreal Cognitive Assessment

    It is a validated test of cognitive impairment. It ranges from 0 (indicating worse cognitive function) to 30 (best cognitive function).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention

Secondary outcomes

  1. Changes in Montreal Cognitive Assessment

    It is a validated test of cognitive impairment. It ranges from 0 (indicating worse cognitive function) to 30 (best cognitive function).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  2. Changes in Symbol Digit Modalities Test

    The Symbol Digit Modalities Test evaluates information processing speed. It consists of a simple task of replacing symbols with numbers. Using a reference key, the patient has 90 seconds to match a sequence of symbols with the correspondent numbers as rapidly as possible. Both written or oral administration can be used. For each correct answer, a point is assigned.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  3. Changes in Tower of London

    The Tower of London test is a tool to assess strategic decision and problem solving. The patient is required to move different colored balls on the three pegs of different lengths, according to a model and a number of established moves. The maximum time for each configuration is 60 seconds.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  4. Changes in Rey-Osterrieth Complex Figure test

    The Rey-Osterrieth Complex Figure is a neuropsychological assessment for evaluation of visuospatial abilities, memory, attention, planning, working memory and executive functions. The patient is required to copy a complex figure freehand (recognition), and then draw it from memory (recall). The score is assigned based on the correctness of each line (from 0 to 2)

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  5. Changes in Visual search test

    It is a validated measure of visual attention.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  6. Changes in Fugl-Meyer Assessment of the Upper Extremity (motor score)

    It is a stroke-specific, performance-based impairment index. It ranges from 0 (hemiplegia) to 66 points (normal).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  7. Changes in Thumb Localizing Test

    It is a standardised measure of proprioception. It ranges from 0 (normal) to 3.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  8. Changes in Semmes Weinstein filament test

    It measure the level of light touch sensation of the tips of the thumb and index finger. The Semmes Weinstein filament test kit consists of 20 flexible nylon monofilaments of constant length, but varying in diameter. They are labeled so as to give a linear scale of perceived intensity (1.65-6.65) using a logarithmic scale of applied force: labeled number = Log10 of (10 × force in milligrams). The more the labeled number increases, the thicker the filament becomes, and the more pressure is necessary to bend the filament.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  9. Changes in Fugl-Meyer Assessment of the Upper Extremity (sensation score)

    It is a stroke-specific, performance-based impairment index. It ranges from 0 (no sensation) to 12 points (normal).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  10. Changes in Box and Block test

    The Box and Block test is a standard measure for evaluating manual dexterity. The participants grasp and transfer one-inch square blocks from one compartment to the other, transferring as many as possible. The number of blocks transferred from one side to the other within 1 min is recorded.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  11. Changes in Motricity Index

    It is a validated measure of upper limb strength. It ranges from 0 (worse) to 100 (normal strength).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  12. Changes in Modified Barthel Index

    The modified is an ordinal scale used to measure performance in activities of daily living. It ranges from 0 to 100, with lower scores indicating increased disability.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  13. Changes in Numerical Rating Scale for Pain

    The Numerical Pain Rating Scale (NPRS) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale, from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  14. Changes in Neuropathic Pain Symptom Inventory

    It is a validated scale for evaluating both peripheral and central neuropathic pain. It ranges from 0 to 100 (most imaginable pain)

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  15. Changes in Douleur Neuropathique 4

    It is a validated clinician-administered screening tool for neuropathic pain. It ranges from 0 to 10; higher values means higher neuropathic pain probability.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  16. Changes in Post-stroke Depression Rating Scale

    It is a validated measure of depression in post-stroke patients. The score ranges from 0 (best) to 45 (worse)

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  17. Changes in Intrinsic Motivation Inventory

    The Intrinsic Motivation Inventory (IMI) is a multidimensional measurement method designed to assess participants' subjective experience related to a target activity in laboratory experiments

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

Other outcomes

  1. Changes in robotic score duration

    The kinematics of the end-effector of the robot will be acquired during reaching tasks performed by the patient without any assistance from the device. Specifically, "Duration" is the time required to complete the task. It is measured in seconds

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  2. Changes in robotic score speed

    The kinematics of the end-effector of the robot will be acquired during reaching tasks performed by the patient without any assistance from the device. Specifically, "Velocity_mean" is the average velocity of the device during the test. It is measured in m/s.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  3. Changes in robotic score length

    The kinematics of the end-effector of the robot will be acquired during reaching tasks performed by the patient without any assistance from the device. Specifically, "Length_tot" is the global length of the path travelled by the subject during center-out movements. It is measured in meters and it ranges from 0 (no movement) to 2.808 m (patient can fully perform the entire task).

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  4. Changes in robotic score useful work

    The kinematics of the end-effector of the robot will be acquired during reaching tasks performed by the patient without any assistance from the device. Specifically, "useful work" is the amount of total work directed towards the target. It is measured in Joules.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  5. Changes in robotic score strength

    The kinetics of the end-effector of the robot will be measured by the robot during reaching tasks performed by the patient against the device. The outcome will be the maximum values towards 8 targets

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  6. Changes in robotic score finger strength (flexion and extension)

    It is the isometric strength for the hand, in both flexion and extension

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  7. Changes in robotic score muscle tone at rest

    It is the passive baseline force of the finger muscles.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  8. Changes in matching test mean error

    The mean value of the absolute differences between the actual and the desired positions.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

  9. Changes in matching test variability

    The standard deviation of the matching errors across trials.

    Time frame: Baseline, up to 7 days after the enrollment; up to 3 days after the intervention; 6 months after the end of the intervention

07

Study locations

3 of 3 sites recruiting
  • IRCCS Fondazione Don Carlo Gnocchi
    Firenze, 50143, Italy
    Recruiting
  • IRCCS Centro Neurolesi Bonino Pulejo
    Messina, 98123, Italy
    Recruiting
  • Fondazione Don Carlo Gnocchi - Centro Santa Maria della Provvidenza
    Roma, 00166, Italy
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06109324
Lead sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
IRCCS Centro Neurolesi Bonino Pulejo, Scuola Superiore Sant'Anna di Pisa
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Nov 13, 2023
Primary completion
May 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Marco Germanotta, PhD
Contact
mgermanotta@dongnocchi.it
+390633086553
Marco Germanotta, PhD
study director · IRCCS Fondazione Don Carlo Gnocchi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion